# Yuhan Corporation

Source: https://onco.cc/companies/yuhan/  
OnCo record `yuhan` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Yuhan Corporation is a South Korea-based pharmaceutical company that leads 3 cancer trials in OnCo, testing the immuno-oncology candidates YH32364, YH32367 and YH42946 in non-small-cell lung cancer and advanced solid tumours.

## Summary

Yuhan Corporation is a South Korean pharmaceutical company founded in 1926 that makes prescription medicines, health supplements, household and animal health products. Its research pipeline includes the lung cancer drug lazertinib and immuno-oncology candidates such as YH32364 and YH32367. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT06616766 (phase 1/2, A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK an...), NCT06975410 (phase 1/2, Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpr...) and NCT05523947 (phase 1/2, Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Yuhan; 유한양행
- Tags: ctgov-sponsor
- HQ: Seoul
- Type: pharma
- Website: https://www.yuhan.co.kr
- Ticker: KRX:000100

## Sources

- Official website: https://www.yuhan.co.kr
- ClinicalTrials.gov: trials led by Yuhan Corporation: https://clinicaltrials.gov/search?lead=Yuhan%20Corporation

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- trials: [A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946](https://onco.cc/trials/nct06616766/), [Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors](https://onco.cc/trials/nct06975410/), [Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor](https://onco.cc/trials/nct05523947/)

---
JSON: https://onco.cc/api/v1/entities/yuhan.json